Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2011

01-08-2011 | Original Paper

The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival

Authors: Anna G. Antonacopoulou, Konstantina Floratou, Vasiliki Bravou, Anastasia Kottorou, Fotinos-Ioannis Dimitrakopoulos, Stella Marousi, Michalis Stavropoulos, Angelos K. Koutras, Chrisoula D. Scopa, Haralabos P. Kalofonos

Published in: Cellular Oncology | Issue 4/2011

Login to get access

Abstract

Background

Survivin is involved in the regulation of cell division and survival, two key processes in cancer. The majority of studies on survivin in colorectal cancer (CRC) have focused on protein expression and less is known about the expression of survivin splicing variants or survivin gene polymorphisms in CRC. In the present study, the mRNA levels of the five known isoforms of survivin as well as survivin protein were assessed in matched normal and neoplastic colorectal tissue. Moreover, the 9386 C/T and -31 G/C polymorphisms were investigated.

Methods

Quantitative RT-PCR was used to assess mRNA levels in fresh/frozen tissue samples. Protein levels were immunohistochemically evaluated on formalin-fixed paraffin-embedded tissue sections. Individuals were genotyped using real time PCR

Results

Expression of all 5 survivin splice variants as well as survivin protein was elevated in colorectal carcinomas compared to normal tissue. Specific splice variant expression differentially correlated with clinicopathological parameters. Furthermore, both snps correlated with splice variant levels or their ratios in colorectal carcinomas while the -31 G/C snp may be related to CRC development and improved overall survival.

Conclusion

Our results support a role of survivin in colorectal carcinogenesis while the -31 G/C snp may constitute a marker of survival.
Literature
1.
2.
F. Li, G. Ambrosini, E.Y. Chu, J. Plescia, S. Tognin, P.C. Marchisio, D.C. Altieri, Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580–584 (1998)PubMedCrossRef
3.
G. Ambrosini, C. Adida, D.C. Altieri, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917–921 (1997)PubMedCrossRef
4.
K. Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto, N. Tanigawa, Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 6, 127–134 (2000)PubMed
5.
M. Monzo, R. Rosell, E. Felip, J. Astudillo, J.J. Sanchez, J. Maestre, C. Martin, A. Font, A. Barnadas, A. Abad, A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17, 2100–2104 (1999)PubMed
6.
H. Kawasaki, D.C. Altieri, C.D. Lu, M. Toyoda, T. Tenjo, N. Tanigawa, Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58, 5071–5074 (1998)PubMed
7.
F. Li, X. Ling, Survivin study: an update of “what is the next wave”? J. Cell. Physiol. 208, 476–486 (2006)PubMedCrossRef
8.
C. Mahotka, M. Wenzel, E. Springer, H.E. Gabbert, C.D. Gerharz, Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59, 6097–6102 (1999)PubMed
9.
A. Badran, A. Yoshida, K. Ishikawa, T. Goi, A. Yamaguchi, T. Ueda, M. Inuzuka, Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem. Biophys. Res. Commun. 314, 902–907 (2004)PubMedCrossRef
10.
S.K. Knauer, C. Bier, P. Schlag, J. Fritzmann, W. Dietmaier, F. Rodel, L. Klein-Hitpass, A.F. Kovacs, C. Doring, M.L. Hansmann, W.K. Hofmann, M. Kunkel, C. Brochhausen, K. Engels, B.M. Lippert, W. Mann, R.H. Stauber, The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 6, 1502–1509 (2007)PubMed
11.
H. Caldas, L.E. Honsey, R.A. Altura, Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol. Cancer 4, 11 (2005)PubMedCrossRef
12.
Y. Xu, F. Fang, G. Ludewig, G. Jones, D. Jones, A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 23, 527–537 (2004)PubMed
13.
J.S. Jang, K.M. Kim, K.H. Kang, J.E. Choi, W.K. Lee, C.H. Kim, Y.M. Kang, S. Kam, I.S. Kim, J.E. Jun, T.H. Jung, J.Y. Park, Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60, 31–39 (2008)PubMedCrossRef
14.
A.A. Borbely, M. Murvai, K. Szarka, J. Konya, L. Gergely, Z. Hernadi, G. Veress, Survivin promoter polymorphism and cervical carcinogenesis. J. Clin. Pathol. 60, 303–306 (2007)PubMedCrossRef
15.
W.H. Majoros, U. Ohler, Spatial preferences of microRNA targets in 3′ untranslated regions. BMC Genomics 8, 152 (2007)PubMedCrossRef
16.
L.M. Veenendaal, O. Kranenburg, N. Smakman, A. Klomp, I.H. Borel Rinkes, P.J. van Diest, Differential Notch and TGFbeta signaling in primary colorectal tumors and their corresponding metastases. Cell. Oncol. 30, 1–11 (2008)PubMed
17.
W.E. Mesker, G.J. Liefers, J.M. Junggeburt, G.W. van Pelt, P. Alberici, P.J. Kuppen, N.F. Miranda, K.A. van Leeuwen, H. Morreau, K. Szuhai, R.A. Tollenaar, H.J. Tanke, Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell. Oncol. 31, 169–178 (2009)PubMed
18.
H. Kawasaki, M. Toyoda, H. Shinohara, J. Okuda, I. Watanabe, T. Yamamoto, K. Tanaka, T. Tenjo, N. Tanigawa, Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91, 2026–2032 (2001)PubMedCrossRef
19.
L.F. Fan, W.G. Dong, C.Q. Jiang, Q. Qian, Q.F. Yu, Role of Hypoxia-inducible factor-1 alpha and Survivin in colorectal carcinoma progression. Int. J. Colorectal Dis. 23, 1057–1064 (2008)PubMedCrossRef
20.
S. Lassmann, L. Tang, M. Capanu, T. Brabletz, A. Schopflin, A. Zur Hausen, M. Gonen, N. Kemeny, J. Shia, D. Klimstra, M. Werner, Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy. Gastroenterology 133, 1831–1839 (2007)PubMedCrossRef
21.
S. Rozen, H. Skaletsky, Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365–386 (2000)PubMed
22.
A.G. Antonacopoulou, P.D. Grivas, L. Skarlas, M. Kalofonos, C.D. Scopa, H.P. Kalofonos, POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance? Anticancer Res. 28, 1221–1227 (2008)PubMed
23.
P.D. Grivas, A. Antonacopoulou, V. Tzelepi, G. Sotiropoulou-Bonikou, Z. Kefalopoulou, A.G. Papavassiliou, H. Kalofonos, HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. Eur. J. Cancer 43, 2602–2611 (2007)PubMedCrossRef
24.
K. Suga, T. Yamamoto, Y. Yamada, S. Miyatake, T. Nakagawa, N. Tanigawa, Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol. Rep. 13, 891–897 (2005)PubMed
25.
F. Vegran, R. Boidot, C. Oudin, J.M. Riedinger, S. Lizard-Nacol, Distinct expression of Survivin splice variants in breast carcinomas. Int. J. Oncol. 27, 1151–1157 (2005)PubMed
26.
S. Lankiewicz, E. Rother, S. Zimmermann, C. Hollmann, F. Korangy, T.F. Greten, Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell. Oncol. 30, 463–471 (2008)PubMed
27.
S. De Maria, G. Pannone, P. Bufo, A. Santoro, R. Serpico, S. Metafora, C. Rubini, D. Pasquali, S.M. Papagerakis, S. Staibano, G. De Rosa, E. Farina, M. Emanuelli, A. Santarelli, M.A. Mariggio, L. Lo Russo, L. Lo Muzio, Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 135, 107–116 (2009)PubMedCrossRef
28.
T. Zhang, T. Otevrel, Z. Gao, Z. Gao, S.M. Ehrlich, J.Z. Fields, B.M. Boman, Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 61, 8664–8667 (2001)PubMed
29.
N. Zhu, L. Gu, H.W. Findley, F. Li, M. Zhou, An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23, 7545–7551 (2004)PubMedCrossRef
30.
M. Gazouli, N. Tzanakis, G. Rallis, G. Theodoropoulos, I. Papaconstantinou, A. Kostakis, N.P. Anagnou, N. Nikiteas, Survivin -31 G/C promoter polymorphism and sporadic colorectal cancer. Int. J. Colorectal Dis. 24, 145–150 (2009)PubMedCrossRef
31.
J.G. Kalliakmanis, C. Kouvidou, C. Latoufis, G. Kouvatseas, D. Anagnostakis, G. Papatheodoridis, J. Koskinas, A. Archimandritis, Survivin expression in colorectal carcinomas: correlations with clinicopathological parameters and survival. Dig. Dis. Sci. 55, 2958–2964 (2009)PubMedCrossRef
32.
P.N. Span, V.C. Tjan-Heijnen, J.J. Heuvel, J.B. de Kok, J.A. Foekens, F.C. Sweep, Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin. Chem. 52, 1693–1700 (2006)PubMedCrossRef
33.
K. Komuro, M. Tada, E. Tamoto, A. Kawakami, A. Matsunaga, K. Teramoto, G. Shindoh, M. Takada, K. Murakawa, M. Kanai, N. Kobayashi, Y. Fujiwara, N. Nishimura, J. Hamada, A. Ishizu, H. Ikeda, S. Kondo, H. Katoh, T. Moriuchi, T. Yoshiki, Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. J. Surg. Res. 124, 216–224 (2005)PubMedCrossRef
34.
R. Kannangai, J. Wang, Q.Z. Liu, F. Sahin, M. Torbenson, Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int. J. Gastrointest. Cancer 35, 53–60 (2005)PubMedCrossRef
35.
B. Ryan, N. O’Donovan, B. Browne, C. O’Shea, J. Crown, A.D. Hill, E. McDermott, N. O’Higgins, M.J. Duffy, Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br. J. Cancer 92, 120–124 (2005)PubMedCrossRef
36.
F. Li, J. Yang, N. Ramnath, M.M. Javle, D. Tan, Nuclear or cytoplasmic expression of survivin: what is the significance? Int. J. Cancer 114, 509–512 (2005)PubMedCrossRef
37.
W.S. Moon, A.S. Tarnawski, Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Hum. Pathol. 34, 1119–1126 (2003)PubMedCrossRef
38.
S. Peroukides, V. Bravou, A. Alexopoulos, J. Varakis, H. Kalofonos, H. Papadaki, Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol. Histopathol. 25, 299–307 (2010)PubMed
Metadata
Title
The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival
Authors
Anna G. Antonacopoulou
Konstantina Floratou
Vasiliki Bravou
Anastasia Kottorou
Fotinos-Ioannis Dimitrakopoulos
Stella Marousi
Michalis Stavropoulos
Angelos K. Koutras
Chrisoula D. Scopa
Haralabos P. Kalofonos
Publication date
01-08-2011
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2011
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-011-0038-4

Other articles of this Issue 4/2011

Cellular Oncology 4/2011 Go to the issue

Original Paper

Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer—indications for anti-TNF-α agents in cancer treatment

Original Paper

Rapid quantification of myocardial fibrosis: a new macro-based automated analysis

Original Paper

The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer

Original Paper

Genetic profile of adenoid cystic carcinomas (ACC) with high-grade transformation versus solid type

Original Paper

Gene expression in oligodendroglial tumors

Original Paper

High Acute Myeloid Leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits